Trastuzumab (trade name Herceptin, Hoffman-La Roche Ltd., Mississauga, ON, Canada) is a biologic drug used with chemotherapy to treat HER2+/neu-overexpressing adjuvant breast, advanced gastric, gastroesophageal, and esophageal cancers [2]. Here, ERBB2 is linked to esophageal cancer.